The WHI Estrogen-Alone Trial - Do Things Look Any Better?

JAMA

Volumn 291, Issue 14, 2004, Pages 1769-1771

  Hulley, Stephen B ^a   Grady, Deborah ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; GESTAGEN; PLACEBO; ESTROGEN;

BREAST CANCER; CANCER SUSCEPTIBILITY; CLINICAL TRIAL; COLON CANCER; DISEASE EXACERBATION; EDITORIAL; ENDOMETRIUM CANCER; ESTROGEN THERAPY; HIP FRACTURE; HUMAN; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; MENOPAUSAL SYNDROME; OSTEOPOROSIS; PRIORITY JOURNAL; STROKE; VENOUS THROMBOEMBOLISM; CORONARY ARTERY DISEASE; FEMALE; MENOPAUSE; NOTE; POSTMENOPAUSE; RISK ASSESSMENT;

CORONARY DISEASE; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; MENOPAUSE; POSTMENOPAUSE; RISK ASSESSMENT;

EID: 1842831345     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.291.14.1769     Document Type: Editorial

References (25)

1. Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health. 1998;19:55-72.
2. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340:1801-1811.
3. Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA. 1995;273:199-208.
4. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol. 1995;85:304-313.
5. Hulley S, Grady D, Bush T, et al, for the Heart and Estrogen/progestin Replacement Study Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-613.
6. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
7. Simon JA, Hsia J, Cauley JA, et al. Postmenopausal hormone therapy and risk of stroke. Circulation. 2001;103:638-642.
8. Shumaker SA, Legault C, Thal L, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289:2651-2662.
9. Stephenson J. FDA orders estrogen safety warnings. JAMA. 2002;289:537-538.
10. Mosca L, Collins P, Herrington DM, et al. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 2001;104:499-503.
11. American College of Obstetricians and Gynecologists. Questions and answers on hormone therapy. Available at: http://www.acog.org/from_home/publications/press_releases/nr08-30-02.cfm? printerFriendly=yes. Accessibility verified March 24, 2004.
12. Ettinger B, Grady D, Tosteson AN, Pressman A, Macer JL. Effect of Women's Health Initiative findings on women's decisions to discontinue postmenopausal hormone therapy. Obstet Gynecol. 2003;102:2225-2232.
13. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA. 2004;291:47-53.
14. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291:1701-1712.
15. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016-1037.
16. Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA. 1996;276:1389-1396.
17. Fuchs-Young R, Glasebrook AL, Short LL, et al. Raloxifene is a tissue-selective agonist/antagonist that functions through the estrogen receptor. Ann N Y Acad Sci. 1995;761:355-360.
18. Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med. 2001;344:276-285.
19. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet. 1997;350:1047-1059.
20. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362:419-427.
21. Fisher B, Costantino J, Wickerham D, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371-1388.
22. NIH/NHLBI News Release. Statement from Barbara Alving, MD, Director of the Women's Health Initiative and Acting Director of the National Heart, Lung, and Blood Institute. Available at: http://www.nhlbi.nih.gov/new/press/04-03-02.htm. Accessibility verified March 24, 2004.
23. Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. JAMA. 1996;275:370-375.
24. Mosca L, Appel LJ, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation. 2004;109:672-693.
25. Cranney A, Guyatt G, Griffith L, et al. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev. 2002;23:570-578.